A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 µg and 160/18/9.6 µg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol. (2019)

First Author: Rabe KF

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.rmed.2019.08.010

PubMed Identifier: 31605923

Publication URI: http://europepmc.org/abstract/MED/31605923

Type: Journal Article/Review

Volume: 158

Parent Publication: Respiratory medicine

ISSN: 0954-6111